X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Apabetalone (RVX000222), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease progression.
Lead Product(s): Apabetalone,Atorvastatin,Rosuvastatin
Therapeutic Area: Endocrinology Product Name: RVX000222
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
Apabetalone (RVX-208/RVX000222), is first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action, is selective BET inhibitor that works in preventing and treating disease progression by regulating the expression of disease-causing genes.
Lead Product(s): Apabetalone
Therapeutic Area: Cardiology/Vascular Diseases Product Name: RVX000222
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
RVX-208 (apabetalone), is first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 selective BET inhibitor that works in preventing and treating disease progression by regulating expression of disease-causing genes.
Lead Product(s): Apabetalone
Therapeutic Area: Infections and Infectious Diseases Product Name: RVX-208
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
Apabetalone’s unique dual epigenetic mechanism may help stop disease progression by regulating the expression of disease and inflammation causing genes, without altering DNA.
Lead Product(s): Apabetalone
Therapeutic Area: Infections and Infectious Diseases Product Name: RVX-208
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2022
Details:
The Supreme Council of the Arab-African Economy is pleased to be in collaboration with Resverlogix to provide the necessary investment and assistance to support the emergence of apabetalone (RVX-208) into the Arab-African Economy.
Lead Product(s): Apabetalone
Therapeutic Area: Infections and Infectious Diseases Product Name: RVX-208
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Supreme Council of the Arab-African Economy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 03, 2021
Details:
Apabetalone (RVX-208), a first-in-class, epigenetic small molecule, or gene regulating, therapeutic candidate. It is a selective BET (bromodomain and extra-terminal) inhibitor, which works in preventing disease by turning genes on and off through regulation of gene expression.
Lead Product(s): Apabetalone
Therapeutic Area: Infections and Infectious Diseases Product Name: RVX-208
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2021
Details:
Apabetalone (RVX-208), is a first-in-class, epigenetic small molecule, or gene regulating, therapeutic candidate. It is a selective BET inhibitor, which works in preventing disease by turning genes on and/or off through regulation of gene expression.
Lead Product(s): Apabetalone
Therapeutic Area: Infections and Infectious Diseases Product Name: RVX-208
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2021
Details:
Apabetalone inhibits SARS-CoV-2 infection in vitro to levels comparable to those of antiviral agents. The study supports further evaluation of apabetalone to treat COVID-19, either alone or in combination with emerging therapeutics.
Lead Product(s): Apabetalone
Therapeutic Area: Infections and Infectious Diseases Product Name: RVX-208
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2021
Details:
The planned Phase 2 trial will be an open-label study evaluating the safety and efficacy of oral apabetalone, in combination with standard of care for patients hospitalized with COVID-19.
Lead Product(s): Apabetalone
Therapeutic Area: Infections and Infectious Diseases Product Name: RVX-208
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2021
Details:
In BETonMACE study, significantly fewer hospitalizations for heart failure (HHF) in patients with type 2 diabetes and a recent history of acute coronary syndrome (ACS) were observed in the apabetalone treatment group compared to placebo.
Lead Product(s): Apabetalone
Therapeutic Area: Cardiology/Vascular Diseases Product Name: RVX-208
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
